Skip to content
Bored Studies
RecruitingPhase 2

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

Novartis Pharmaceuticals · NCT07543120

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
323
US sites recruiting
19
Study start
May 7, 2026
Record last updated
July 30, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.

Being studied: QCZ484

Conditions: Hypertension (HTN)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Signed informed consent must be obtained prior to participation in the study.
  • Successful completion of treatment period on QCZ484 study medication in parent study.
  • No significant safety issue that may place participant at safety risk as determined by the Investigator.

Exclusion Criteria

Participants meeting any of the following criteria, may it be pre-existing or developed during the parent study, are not eligible for inclusion in this study:

  • Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator.
  • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study.
  • Permanent or persistent atrial fibrillation developed during the parent study.
  • Clinically significant valvular heart disease developed during the parent study.
  • Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to enrollment.

Other protocol-defined inclusion/exclusion criteria may apply

Recruiting US locations

  • NICRs Research Center

    Garden Grove, CA 92844

    Site contact: Maria Murillo · +1 909 206 2454 · mmurillo@nicresearch.com

  • Downtown L A Research Center Inc

    Los Angeles, CA 90017

    Site contact: Claudia Cisneros · +1 213 261 3680 · ccisneros@dtlaresearch.com

  • Clinical Research of Brandon LLC

    Brandon, FL 33511

    Site contact: Erika Santos · esantos@crofb.com

  • Entrust Clinical Research

    Miami, FL 33176

    Site contact: Daimelys Garcia · Dgarcia@entrustclinicalresearch.com

  • Inpatient Research Clinical LLC

    Miami Lakes, FL 33014

    Site contact: Ilianys Marino · +1 786 502 4303 · imarino@inpatientresearch.com

  • American Research Centers of FL

    Pembroke Pines, FL 33027

    Site contact: Liliana Portal · lportal@americanresearchcenters.com

  • Cen Exel FCR

    Tampa, FL 33613

    Site contact: Kaylie Locascio · k.locascio@cenexel.com

  • Cardiology Partners Clinical Research Institute

    Wellington, FL 33449

    Site contact: Hiromi Hauserman · +1 561 537 4778 · hiromi.hauserman@cardiologypartnerspl.com

  • Javara Research

    Fayetteville, GA 30214

    Site contact: Shemeka Williams · 229 518 4947 · swilliams@javararesearch.com

  • Eagle Clinical Research

    Chicago, IL 60621

    Site contact: Iesha Griffin · igriffin@eagleclinicalresearch.com

  • Alliance for Multispecialty Research

    Wichita, KS 67207

    Site contact: Layla Maxwell · layla.maxwell@amr-clinical.com

  • Anderson Medical Research

    Ft. Washington, MD 20744

    Site contact: Ann-Marie Cobb · andersonmedicalresearch@gmail.com

  • Oakland Medical Research Center

    Troy, MI 48085

    Site contact: Julie Lafave · +1 248 828 7500 · jlafave@oaklandmedicalresearch.com

  • Jefferson City Medical Group

    Jefferson City, MO 65109

    Site contact: Suzin Cunningham · suzin.cunningham@avacare.com

  • CenExel HRI

    Berlin, NJ 08009

    Site contact: Danielle Brudon · +1 856 452 9901#802 · d.brudon@cenexel.com

  • Monroe Biomedical Research

    Monroe, NC 28112

    Site contact: Maya Patterson · +1 704 283 7359 · Maya.Patterson@monroeresearch.com

  • Conrad Clinical Research

    Edmond, OK 73013

    Site contact: Shelly Todd · stodd@oktrials.com

  • Clinical Neuroscience Solutions Inc

    Memphis, TN 38119

    Site contact: Melissa Flowers · +1 901 843 1045 · mflowers@cnshealthcare.com

  • Sun Research Institute

    San Antonio, TX 78205

    Site contact: Chandana Gagireddy · cgagireddy@sunresearch.com

Study contacts (from the official record)

  • Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
  • Novartis Pharmaceuticals · +41613241111
All heart & blood pressure studies in California →
An Open-label Extension Safety and Efficacy Study of QCZ484 in… (NCT07543120) | Bored Studies